# Irreversible Electroporation & Pembro Immunotherapy in Locally Advanced Pancreatic Cancer

> **NCT06378047** · PHASE1 · COMPLETED · sponsor: **H. Lee Moffitt Cancer Center and Research Institute** · enrollment: 2 (actual)

## Conditions studied

- Pancreatic Cancer
- Locally Advanced Pancreatic Cancer

## Interventions

- **DRUG:** Pembrolizumab
- **DEVICE:** Irreversible Electroporation

## Key facts

- **NCT ID:** NCT06378047
- **Lead sponsor:** H. Lee Moffitt Cancer Center and Research Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2024-04-10
- **Primary completion:** 2025-09-15
- **Final completion:** 2025-09-15
- **Target enrollment:** 2 (ACTUAL)
- **Last updated:** 2026-02-09

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06378047

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06378047, "Irreversible Electroporation & Pembro Immunotherapy in Locally Advanced Pancreatic Cancer". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06378047. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*